Amgen Inc.

Other

Monsanto Company

Hecht, Randy I.

Klopf, Lori L.

Randy Ira Hecht

Mark Leo Michaels

Edward John Belouski

Jeonghoon Sun

Yue-Sheng Li

Jing M Xu

Murielle Marie Ellison

Agnes Eva Hamburger

Michael B Mann

Christopher Francis Toombs

Mary Ann Pelleymounter

Randal Robert Ketchem

Kenneth William Walker

Colin V Gegg

Colin Victor Gegg, Jr

Jason Charles O'Neill

Jing Xu

Mary Ann Pellymounter

Lori L Klopf

Murielle M Ellison

The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

Methods of treating non-alcoholic steatohepatitis using FGF21 mutants

The invention provides methods for treating non-alcoholic steatohepatitis (NASH) using FGF21 mutant polypeptides.

There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.

Variants of tissue inhibitor of metalloproteinase type three (TIMP-3), compositions and methods

The invention provides methods of treating diabetes, reducing triglyceride levels, and treating obesity by administering to a subject in need there a fusion protein comprising an FGF21 mutant.

Methods of treating of diabetes and obesity using FGF21 mutants

The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. In some embodiments, the FGF21 mutant polypeptide comprises a substitution at position 98, 171 and/or 180.

FGF21 mutants comprising a mutation at position 98, 171 and/or 180

The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides comprising extended in vivos half-lives, pharmaceutical compositions comprising FGF21 mutant polypeptides having extended in vivos half lives, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

FGF-21 mutants comprising polyethylene glycol and uses thereof

The invention provides FGF21 mutant polypeptides with reduced proteolysis and aggregation, pharmaceutical compositions comprising the same.

FGF mutants with reduced proteolysis and aggregation

The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, wherein the FGF 21 mutant polypeptides comprise two or more mutations, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

FGF21 polypeptides comprising two or more mutations and uses thereof

FGF 21 polypeptides comprising two or more mutations and uses thereof

The invention provides nucleic acid molecules encoding FGF21 mutant fusion polypeptides comprising mutations at positions 98, 171, 179, 180 or 181, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.

FGF21 mutant fusion polypeptides and uses thereof

The invention provides a multimer comprising at least a first and a second chain, the first chain comprising the polypeptide of SEQ ID NO:4, wherein the leucine at position 98 is substituted with an arginine; the proline at position 171 is substituted with glycine; and the alanine at position 180 is substituted with glutamic acid; a linker sequence comprising SEQ ID NO:31; and an Fe domain comprising SEQ NO:11; and a second chain comprising the polypeptide of SEQ ID NO:4, wherein the leucine at position 98 is substituted with an arginine; the proline at position 171 is substituted with glycine; and the alanine at position 180 is substituted with glutamic acid; a linker sequence comprising SEQ ID NO:31; and an Fe domain comprising SEQ ID NO:11, nucleic acids encoding the multimer, pharmaceutical compositions comprising the multimer and methods for treating metabolic disorders using such nucleic acids, multimers or pharmaceutical compositions.

FGF21 mutants multimers and uses thereof

FGF21 mutants and uses thereof

Uses of FGF21 polypeptides comprising two or more mutations

The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or analog.

Growing community of inventors

Thousand Oaks, CA, United States of America

Randy Ira Hecht